MCID: FLL029
MIFTS: 35

Fallopian Tube Disease

Categories: Reproductive diseases

Aliases & Classifications for Fallopian Tube Disease

MalaCards integrated aliases for Fallopian Tube Disease:

Name: Fallopian Tube Disease 12 15
Fallopian Tube Diseases 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1962
MeSH 44 D005184
NCIt 50 C26771
SNOMED-CT 68 128134005
UMLS 73 C0015556

Summaries for Fallopian Tube Disease

MalaCards based summary : Fallopian Tube Disease, also known as fallopian tube diseases, is related to acrodermatitis chronica atrophicans and selective igg deficiency disease. An important gene associated with Fallopian Tube Disease is OVGP1 (Oviductal Glycoprotein 1), and among its related pathways/superpathways is Primary immunodeficiency. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and t cells.

Wikipedia : 76 The Fallopian tubes, also known as uterine tubes or salpinges (singular salpinx), are two very fine... more...

Related Diseases for Fallopian Tube Disease

Diseases related to Fallopian Tube Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)
# Related Disease Score Top Affiliating Genes
1 acrodermatitis chronica atrophicans 10.7 CD40LG OVGP1
2 selective igg deficiency disease 10.6 CD40LG CD79A
3 c1q nephropathy 10.6 CD40LG CD79A
4 meningovascular neurosyphilis 10.6 CD40LG CD79A
5 alpha chain disease 10.6 CD40LG CD79A
6 brill-zinsser disease 10.6 CD40LG CD79A
7 exudative glomerulonephritis 10.6 CD40LG CD79A
8 cork-handlers' disease 10.6 CD40LG CD79A
9 salpingo-oophoritis 10.6 CD40LG CD79A
10 early yaws 10.6 CD40LG CD79A
11 ventilation pneumonitis 10.6 CD40LG CD79A
12 chronic interstitial cystitis 10.6 CD40LG CD79A
13 axillary adenitis 10.6 CD40LG CD79A
14 cryofibrinogenemia 10.6 CD40LG CD79A
15 trichostrongyloidiasis 10.6 CD40LG CD79A
16 subacute bacterial endocarditis 10.6 CD40LG CD79A
17 heterophyiasis 10.6 CD40LG CD79A
18 immunoglobulin g deficiency 10.6 CD40LG CD79A
19 orbital granuloma 10.6 CD40LG CD79A
20 transient hypogammaglobulinemia of infancy 10.6 CD40LG CD79A
21 hyperglobulinemic purpura 10.6 CD40LG CD79A
22 gastroduodenitis 10.6 CD40LG CD79A
23 bacterial conjunctivitis 10.6 CD40LG CD79A
24 heavy chain disease 10.6 CD40LG CD79A
25 ophthalmia neonatorum 10.6 CD40LG CD79A
26 immunoglobulin a deficiency 1 10.5 CD40LG CD79A
27 parotid disease 10.5 CD40LG CD79A
28 cerebral arteritis 10.5 CD40LG CD79A
29 selective immunoglobulin deficiency disease 10.5 CD40LG CD79A
30 geniculate herpes zoster 10.5 CD40LG CD79A
31 erythema elevatum diutinum 10.5 CD40LG CD79A
32 sporotrichosis 10.5 CD40LG CD79A
33 hyperimmunoglobulin syndrome 10.5 CD40LG CD79A
34 congenital syphilis 10.5 CD40LG CD79A
35 polyclonal hypergammaglobulinemia 10.5 CD40LG CD79A
36 monoclonal paraproteinemia 10.5 CD40LG CD79A
37 ocular toxoplasmosis 10.5 CD40LG CD79A
38 dysgammaglobulinemia 10.5 CD40LG CD79A
39 congenital hypogammaglobulinemia 10.5 CD40LG CD79A
40 acute maxillary sinusitis 10.5 CD40LG CD79A
41 chronic polyneuropathy 10.5 CD40LG CD79A
42 spinocerebellar ataxia, autosomal recessive 10 10.5 CD40LG CD79A
43 parasitic ichthyosporea infectious disease 10.5 CD40LG CD79A
44 cd40 ligand deficiency 10.5 CD40LG CD79A
45 rhinosporidiosis 10.5 CD40LG CD79A
46 secondary syphilis 10.5 CD40LG CD79A
47 yellow nail syndrome 10.5 CD40LG CD79A
48 chronic salpingitis 10.5 CD79A OVGP1
49 congenital toxoplasmosis 10.5 CD40LG CD79A
50 chorioretinitis 10.5 CD40LG CD79A

Graphical network of the top 20 diseases related to Fallopian Tube Disease:



Diseases related to Fallopian Tube Disease

Symptoms & Phenotypes for Fallopian Tube Disease

Drugs & Therapeutics for Fallopian Tube Disease

Drugs for Fallopian Tube Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 360)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
3
Ifosfamide Approved Phase 2, Phase 3,Phase 3 3778-73-2 3690
4
Mechlorethamine Approved, Investigational Phase 2, Phase 3,Phase 3 51-75-2 4033
5
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
10
Cisplatin Approved Phase 3,Phase 1,Phase 2,Not Applicable 15663-27-1 84093 441203 2767
11
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
12
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
13
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
14
Epirubicin Approved Phase 3 56420-45-2 41867
15
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
16
Olaparib Approved Phase 3,Phase 2,Phase 1 763113-22-0 23725625
17
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
18
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
19
Rucaparib Approved, Investigational Phase 3,Phase 2,Phase 1 283173-50-2 9931954
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
21
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 59-30-3 6037
23
Pyridoxal Approved, Nutraceutical Phase 3 66-72-8 1050
24
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
25
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2,Not Applicable 58-05-9 143 6006
26
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Early Phase 1 56-86-0 33032
27
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
28
Trebananib Investigational Phase 3,Phase 2,Phase 1 894356-79-7
29
Saracatinib Investigational Phase 2, Phase 3 379231-04-6
30
Cediranib Investigational Phase 3,Phase 2,Phase 1 288383-20-0 9933475
31
Maleic acid Experimental Phase 3,Phase 2,Phase 1 110-16-7 444266
32 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
33 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
35 Alkylating Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
36 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
37
Isophosphamide mustard Phase 2, Phase 3,Phase 3 0
38 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
39 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
41 Bone Density Conservation Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
42 Estrogen Antagonists Phase 3,Phase 2
43 Estrogen Receptor Modulators Phase 3,Phase 2
44 Estrogens Phase 3,Phase 2
45 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
46 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
48 Selective Estrogen Receptor Modulators Phase 3,Phase 2
49 taxane Phase 3,Phase 2,Phase 1,Not Applicable
50 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 522)
# Name Status NCT ID Phase Drugs
1 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
2 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
3 Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
4 Accelerating Gastrointestinal Recovery Completed NCT01704651 Phase 3 Alvimopan;Placebo
5 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
6 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
7 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Completed NCT01196741 Phase 2, Phase 3 Paclitaxel;Saracatinib;Matched placebo
8 Study of Paclitaxel in Patients With Ovarian Cancer Completed NCT00989131 Phase 3 Paclical®;Taxol®
9 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
10 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00098878 Phase 3 carboplatin
11 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
12 Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Completed NCT00443196 Phase 2, Phase 3
13 A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma Completed NCT00434642 Phase 3 Carboplatin;Gemcitabine;Bevacizumab;Placebo
14 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
15 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
16 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
17 Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
18 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
19 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
20 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
21 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003636 Phase 3 carboplatin;cisplatin
22 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Completed NCT00191646 Phase 3 Gemcitabine;Paclitaxel;Carboplatin
23 A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. Completed NCT00191607 Phase 3 Gemcitabine;liposomal doxorubicin
24 Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
25 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed NCT00003120 Phase 3 paclitaxel
26 Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer Completed NCT00052468 Phase 3 TCG;TC
27 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
28 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
29 Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
30 Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
31 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00002895 Phase 3 chemotherapy
32 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03038100 Phase 3 Paclitaxel;Carboplatin;Atezolizumab;Bevacizumab;Atezolizumab Placebo
33 Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23 Recruiting NCT02903004 Phase 3 Trabectedin;Pegylated Liposomal Doxorubicin;Topotecan;Gemcitabine;Weekly Paclitaxel;Carboplatin
34 A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy Recruiting NCT03522246 Phase 3 Rucaparib;Nivolumab;Placebo Oral Tablet;Placebo IV Infusion
35 Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) Recruiting NCT02859038 Phase 3
36 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Recruiting NCT02855944 Phase 3 Chemotherapy;Rucaparib
37 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
38 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
39 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma Recruiting NCT02328716 Phase 3 Hipec with Cisplatin
40 Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? Recruiting NCT01611766 Phase 3 Salvage Chemotherapy
41 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
42 A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT01846611 Phase 3 Trabectedin;DOXIL;Dexamethasone;DOXIL
43 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Active, not recruiting NCT01849874 Phase 3 MEK162, MEK inhibitor; oral;Physician's choice chemotherapy
44 PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer Active, not recruiting NCT02631876 Phase 3 IMGN853;Paclitaxel;Doxorubicin;Topotecan
45 A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Active, not recruiting NCT01968213 Phase 3 Rucaparib;Placebo
46 Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial Active, not recruiting NCT01506856 Phase 2, Phase 3 Paclitaxel(intravenous) + Carboplatin(intravenous);Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
47 Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer Active, not recruiting NCT01462890 Phase 3 Paclitaxel;Carboplatin
48 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
49 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
50 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel

Search NIH Clinical Center for Fallopian Tube Disease

Cochrane evidence based reviews: fallopian tube diseases

Genetic Tests for Fallopian Tube Disease

Anatomical Context for Fallopian Tube Disease

MalaCards organs/tissues related to Fallopian Tube Disease:

41
Uterus, Ovary, T Cells, Nk Cells, Bone, Testes, Liver

Publications for Fallopian Tube Disease

Articles related to Fallopian Tube Disease:

# Title Authors Year
1
Fallopian tube disease in the nonpregnant patient. ( 21415195 )
2011
2
Fallopian tube disease: the cobblestone pattern as a radiographic sign. ( 11058655 )
2000
3
Fallopian tube disease: limited value of treatment with fallopian tube catheterization. ( 8259393 )
1994

Variations for Fallopian Tube Disease

Expression for Fallopian Tube Disease

Search GEO for disease gene expression data for Fallopian Tube Disease.

Pathways for Fallopian Tube Disease

Pathways related to Fallopian Tube Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.19 CD40LG CD79A

GO Terms for Fallopian Tube Disease

Biological processes related to Fallopian Tube Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 B cell activation GO:0042113 9.26 CD79A HSPD1
2 positive regulation of interleukin-12 production GO:0032735 9.16 CD40LG HSPD1
3 positive regulation of interleukin-10 production GO:0032733 8.96 CD40LG HSPD1
4 B cell proliferation GO:0042100 8.8 CD40LG CD79A HSPD1

Sources for Fallopian Tube Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....